Amikacin target achievement in adult cystic fibrosis patients utilizing Monte Carlo simulation.
Valerie D NoltKyle D PijutElizabeth B AutryWhitney C WilliamsDavid S BurgessDonna R BurgessVaneet AroraRobert J KuhnPublished in: Pediatric pulmonology (2018)
Our data suggests it may not be clinically feasible to utilize amikacin for PsA isolates with a MIC of 16 mg/L. Current guideline dosing recommendations of amikacin 30-35 mg/kg/day are only adequate for PsA with a MIC ≤4 mg/L.